Potential new treatment for stroke

October 3, 2011

Even though stroke is the third leading cause of death in the United States, there is only one approved treatment. Furthermore, fewer than 5% of stroke patients benefit from this treatment. New therapeutic targets are therefore urgently needed. Katrin Andreasson and colleagues, at Stanford University School of Medicine, Stanford, have now identified the protein EP4 as a potential new target for the treatment of stroke. Key to their suggestion that EP4 could provide therapeutic benefit to stroke patients, was the observation that therapeutic systemic administration of a selective EP4 agonist after stroke reduced brain damage and long-term behavioral deficits in mice.

###

TITLE: Signaling via the prostaglandin E2 receptor EP4 exerts neuronal and vascular protection in a mouse model of cerebral ischemia

AUTHOR CONTACT:
Katrin Andreasson
Stanford University School of Medicine, Stanford, California, USA.
Phone: 650.723.1922; Fax: 650.498.6262; E-mail: kandreas@stanford.edu.

View this article at: http://www.jci.org/articles/view/46279?key=403ec32a48be38dd5d20

Contact: Karen Honey
press_releases@the-jci.org
734-546-5242
Journal of Clinical Investigation


Comments

Got something to say? **Please Note** - Comments may be edited for clarity or obscenity, and all comments are published at the discretion of ChattahBox.com - Comments are the opinions of the individuals leaving them, and not of ChattahBox.com or its partners. - Please do not spam or submit comments that use copyright materials, hearsay or are based on reports where the supposed fact or quote is not a matter of public knowledge are also not permitted.